MedPath

Azithromycin with full mouth cleaning in pyorrhoea patients

Phase 1/2
Not yet recruiting
Conditions
Aggressive periodontitis,
Registration Number
CTRI/2020/10/028692
Lead Sponsor
Sharad Pawar Dental College Hospital
Brief Summary

The aim of this randomized clinical trial was to evaluate whether the adjunctive use of systemic azithromycin improves clinical outcomes in the treatment of Stage III Grade B Unstable generalised periodontitis.

**Sample size calculation-**

Sample size was calculated using the data of the previous studies Gazal Jain et al 2018  by using OpenEpi, version 3,open source calculator—SSMean(calculation shown at the end).The result of the calculation is 28, so a around figure of 30 sample will be undertaken for the study.

**Inclusion criteria-**

1.Generalized interproximal attachment loss involving at least three teeth apart from molars and ï¬rst incisors.

2.Amount of microbial deposits inconsistent with the severity of periodontal tissue destruction.

3.Patients with a minimum number of 20 teeth.

4.Patients with clinical attachment loss and probing depths (PDs)  ≥ 4 mm at 2 sites of a minimum of 12 teeth

5.The patients included in the study should be systemically healthy.

6.Patients with no history of periodontal therapy in the preceding 6 months or under any antibiotic therapy.

7.Patients motivated to have the therapy and willing to complete the follow-up.

**Exclusion criteria-**

1.Patients with a known or suspected allergy

2.Patients who have undergone periodontal therapy in the last 6 months.

3.Patients with any systemic disorder affecting periodontal health.

4.Patients with infectious conditions other than periodontitis.

5.Chronic alcoholics

6.Patients consuming tobacco in any form and smokers.

7.Immuno-compromised and systemically-unhealthy patients.

8.Pregnant or lactating females.

**Material and method-** There will be two groups in this study i. Intervantion group ii. Comparator agent. In intervantion group, 15 subjects will be treated with full mouth disinfection (chlorhexidine gel and mouthwash). In comparator agent, 15 subjects will be treated with full mouth disinfection (chlorhexidine gel and mouthwash) with systemic azithromycin 500mg once daily for 7 days.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria
  • 1.Generalized interproximal attachment loss involving at least three teeth apart from molars and ï¬rst incisors.
  • 2.Amount of microbial deposits inconsistent with the severity of periodontal tissue destruction.
  • 3.Patients with a minimum number of 20 teeth.
  • 4.Patients with clinical attachment loss and probing depths (PDs) ≥ 4 mm at 2 sites of a minimum of 12 teeth 5.The patients included in the study should be systemically healthy.
  • 6.Patients with no history of periodontal therapy in the preceding 6 months or under any antibiotic therapy.
  • 7.Patients motivated to have the therapy and willing to complete the follow-up.
Exclusion Criteria
  • 1.Patients with a known or suspected allergy 2.Patients who have undergone periodontal therapy in the last 6 months.
  • 3.Patients with any systemic disorder affecting periodontal health.
  • 4.Patients with infectious conditions other than periodontitis.
  • 5.Chronic alcoholics 6.Patients consuming tobacco in any form and smokers.
  • 7.Immuno-compromised and systemically-unhealthy patients.
  • 8.Pregnant or lactating females.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in Probing Pocket depth (PPD)3 and 6 months
Secondary Outcome Measures
NameTimeMethod
Reduction in Bleeding on Probing (BOP), Gain in Clinical attachment level (CAL)Reduction in Bleeding on Probing (BOP), Gain in Clinical attachment level (CAL) at 3 and 6 months

Trial Locations

Locations (1)

Sharad Pawar Dental College & Hospital

🇮🇳

Wardha, MAHARASHTRA, India

Sharad Pawar Dental College & Hospital
🇮🇳Wardha, MAHARASHTRA, India
Dr chitrika Subhadarsanee
Principal investigator
08763072403
chitrikasubhadarsanee403@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.